Infinity Pharmaceuticals, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2021-12-10: Form 8-K; Period of report 2021-12-10; Description 8.01 Other Events; Details 8.01.
- 2021-11-02: Form 8-K; Period of report 2021-11-02; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2021-09-07: Form 8-K; Period of report 2021-09-01; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2021-07-27: Form 8-K; Period of report 2021-07-27; Description 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2021-12-10 | 8-K | 2021-12-10 | 8.01 Other Events | 8.01 On December 10, 2021, Infinity Pharmaceuticals, Inc. (the “Company”) issued a press release announcing data from MARIO-3 (MAcrophage Reprogramming in Immune Oncology), the Company’s Phase 2 clinical trial evaluating eganelisib in a triple combination in the front-line setting with Tecentriq® (atezolizumab) and Abraxane® (nab-paclitaxel) in patients with unresectable locally advanced or metastatic triple negative breast cancer. | infi-20211210.htm |
| 2021-11-02 | 8-K | 2021-11-02 | 2.02 Results of Operations and Financial Condition | 2.02 On November 2, 2021, Infinity Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results for the quarter ended September 30, 2021 and will conduct a previously announced, publicly available conference call to discuss those results. | infi-20211102.htm |
| 2021-09-07 | 8-K | 2021-09-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 1, 2021, the Board of Directors (the “Board”) of Infinity Pharmaceuticals, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, expanded the size of the Board from six to seven members and elected Dr. Brian Schwartz as a member of the Board, effective September 7, 2021. | brhc10028690_8k.htm |
| 2021-07-27 | 8-K | 2021-07-27 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events | 2.02 On July 27, 2021, Infinity Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results for the quarter ended June 30, 2021. 7.01 On July 27, 2021, the Company intends to present a slide presentation on a conference call reviewing data from MARIO-275, the Company’s randomized, placebo-controlled Phase 2 clinical trial evaluating the efficacy and safety of eganelisib in combination with nivolumab (Opdivo®) in platinum-refractory, I/O naïve patients with advanced urothelial cancer, as well as data from MARIO-3, the Company’s Phase 2 clinical trial evaluating eganelisib in a triple combination in the front-line setting with Tecentriq® (atezolizumab) and Abraxane® (nab-paclitaxel) in patients with unresectable locally advanced or metastatic triple negative breast cancer. 8.01 On July 27, 2021, the Company issued a press release announcing data from MARIO-275 and MARIO-3 clinical trials. | infi-20210727.htm |
| 2021-06-11 | 8-K | 2021-06-10 | 5.07 Submission of Matters to a Vote of Security Holders | nt10025602x2_8k.htm | |
| 2021-05-13 | 8-K | 2021-05-13 | 2.02 Results of Operations and Financial Condition | 2.02 On May 13, 2021, the Company issued a press release announcing its results for the quarter ended March 31, 2021 and will conduct a previously announced, publicly available conference call to discuss those results. | infi-20210513.htm |
| 2021-03-16 | 8-K | 2021-03-16 | 2.02 Results of Operations and Financial Condition | 2.02 On March 16, 2021, Infinity Pharmaceuticals, Inc. issued a press release announcing its results for the year ended December 31, 2020 and will conduct a previously announced, publicly available conference call to discuss those results. | infi-20210316.htm |
| 2021-02-12 | 8-K | 2021-02-11 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On February 11, 2021, the Company issued a press release announcing the launch of the Offering. | nt10020123x6_8k.htm |
| 2021-02-11 | 8-K | 2021-02-11 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On February 11, 2021, Infinity Pharmaceuticals, Inc. (the “Company”) intends to present a slide presentation on a conference call reviewing data from MARIO-275 (MAcrophage Reprogramming in Immune Oncology), a randomized, placebo-controlled Phase 2 study evaluating the efficacy and safety of eganelisib in combination with nivolumab (Opdivo®) in platinum-refractory, I/O naïve patients with advanced urothelial cancer (UC), during the 2021 ASCO Genitourinary Cancers Symposium. 8.01 On February 11, 2021, the Company issued a press release announcing data from MARIO-275. | infi-20210211.htm |
| 2021-01-06 | 8-K | 2021-01-06 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2020, the Company announced on January 6, 2021 that it expects to report that it had approximately $34.1 million in cash and investments (unaudited) as of December 31, 2020. 8.01 On January 6, 2021, the Company issued a press release announcing its 2021 business goals and financial guidance and providing an update regarding MARIO-275, its randomized, placebo controlled Phase 2 study evaluating the benefit of adding eganelisib to nivolumab in platinum-refractory, I/O naïve patients with advanced, metastatic urothelial cancer over nivolumab monotherapy. | infi-20210106.htm |